James D. Brenton | Academic Influence

James D. Brenton's AcademicInfluence.com Rankings

James D. Brenton

Engineering

#7719

World Rank

#9131

Historical Rank

Electrical Engineering

#2417

World Rank

#2532

Historical Rank

engineering Degrees

James D. Brenton

Computer Science

#10446

World Rank

#10972

Historical Rank

Computational Linguistics

#2633

World Rank

#2659

Historical Rank

Machine Learning

#4776

World Rank

#4830

Historical Rank

Artificial Intelligence

#5144

World Rank

#5211

Historical Rank

computer-science Degrees

Download Badge

Engineering
Computer Science

James D. Brenton's Degrees

PhD Computer Science Stanford University
Masters Electrical Engineering University of California, Berkeley

Similar Degrees You Can Earn

Best Online PhD of Computer Science (Doctorates) 2026

Why Is James D. Brenton Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Professor James D Brenton is a clinician scientist and Senior Group Leader at the Cancer Research UK Cambridge Institute and Professor of Ovarian Cancer Medicine in the Department of Oncology, University of Cambridge. He is an Honorary Consultant in Medical Oncology at Addenbrooke's Hospital, Cambridge University Hospitals, Ovarian Cancer Domain Lead for the 100,000 Genomes Project by Genomics England, and co-founder and Clinical Advisor to Inivata Ltd, a clinical cancer genomics company.

(See a Problem?)

James D. Brenton's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups (2012) (4591)
Liquid biopsies come of age: towards implementation of circulating tumour DNA (2017) (1532)
Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA (2013) (1472)
Rethinking ovarian cancer: recommendations for improving outcomes (2011) (1148)
Noninvasive Identification and Monitoring of Cancer Mutations by Targeted Deep Sequencing of Plasma DNA (2012) (1125)
Molecular classification and molecular forecasting of breast cancer: ready for clinical application? (2005) (920)
Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. (2017) (856)
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer (2015) (778)
Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary (2010) (680)
Mutation of FOXL2 in granulosa-cell tumors of the ovary. (2009) (661)
Enhanced detection of circulating tumor DNA by fragment size analysis (2018) (525)
Regulators of mitotic arrest and ceramide metabolism are determinants of sensitivity to paclitaxel and other chemotherapeutic drugs. (2007) (368)
GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer (2013) (350)
Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study. (2013) (339)
CX-5461 is a DNA G-quadruplex stabilizer with selective lethality in BRCA1/2 deficient tumours (2017) (335)
High-resolution aCGH and expression profiling identifies a novel genomic subtype of ER negative breast cancer (2007) (326)
Spatial and Temporal Heterogeneity in High-Grade Serous Ovarian Cancer: A Phylogenetic Analysis (2015) (313)
Ovarian Cancer Cell Line Panel (OCCP): Clinical Importance of In Vitro Morphological Subtypes (2014) (298)
The External RNA Controls Consortium: a progress report (2005) (278)
A gene-expression signature to predict survival in breast cancer across independent data sets (2007) (263)
Copy-number signatures and mutational processes in ovarian carcinoma (2017) (258)
Chromosomal instability determines taxane response (2009) (256)
Optimized p53 immunohistochemistry is an accurate predictor of TP53 mutation in ovarian carcinoma (2016) (254)
Differential expression of selected histone modifier genes in human solid cancers (2006) (250)
Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer (2017) (237)
Unravelling tumour heterogeneity using next-generation imaging: radiomics, radiogenomics, and habitat imaging. (2017) (222)
BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma. (2018) (209)
The Extracellular Matrix Protein TGFBI Induces Microtubule Stabilization and Sensitizes Ovarian Cancers to Paclitaxel (2007) (207)
Deconstruction of a Metastatic Tumor Microenvironment Reveals a Common Matrix Response in Human Cancers. (2018) (206)
Sizing up miRNAs as cancer genes (2005) (204)
Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2. (2017) (198)
Exploratory Analysis of TP53 Mutations in Circulating Tumour DNA as Biomarkers of Treatment Response for Patients with Relapsed High-Grade Serous Ovarian Carcinoma: A Retrospective Study (2016) (183)
Evolution of platinum resistance in high-grade serous ovarian cancer. (2011) (175)
A 1 Mb minimal amplicon at 8p11–12 in breast cancer identifies new candidate oncogenes (2005) (172)
Genomic analysis of genetic heterogeneity and evolution in high-grade serous ovarian carcinoma (2010) (160)
Constitutive p38HOG mitogen-activated protein kinase activation induces permanent cell cycle arrest and senescence. (2002) (158)
High resolution melting for mutation scanning of TP53 exons 5–8 (2007) (143)
Semiquantitative and quantitative dynamic contrast-enhanced magnetic resonance imaging measurements predict radiation response in cervix cancer. (2009) (142)
Phylogenetic Quantification of Intra-tumour Heterogeneity (2013) (136)
Sequential DNA methylation changes are associated with DNMT3B overexpression in colorectal neoplastic progression (2010) (136)
Germline Mutation in BRCA1 or BRCA2 and Ten-Year Survival for Women Diagnosed with Epithelial Ovarian Cancer (2014) (135)
Somatically acquired hypomethylation of IGF2 in breast and colorectal cancer (2008) (135)
Parallel analysis of sporadic primary ovarian carcinomas by spectral karyotyping, comparative genomic hybridization, and expression microarrays. (2002) (130)
Genomic imprinting and cancer. (1995) (124)
p53 immunohistochemistry is an accurate surrogate for TP53 mutational analysis in endometrial carcinoma biopsies (2019) (119)
Using array-comparative genomic hybridization to define molecular portraits of primary breast cancers (2007) (118)
An imprinting element from the mouse H19 locus functions as a silencer in Drosophila (1997) (115)
Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial (2019) (109)
The pitfalls of platform comparison: DNA copy number array technologies assessed (2009) (107)
Complex Stiffness Gradient Substrates for Studying Mechanotactic Cell Migration (2012) (106)
Deletion of a silencer element disrupts H19 imprinting independently of a DNA methylation epigenetic switch. (2000) (102)
A consensus prognostic gene expression classifier for ER positive breast cancer (2006) (98)
Combined image and genomic analysis of high-grade serous ovarian cancer reveals PTEN loss as a common driver event and prognostic classifier (2014) (96)
Results of ARIEL2: A Phase 2 trial to prospectively identify ovarian cancer patients likely to respond to rucaparib using tumor genetic analysis. (2015) (92)
Advanced ovarian cancer: multiparametric MR imaging demonstrates response- and metastasis-specific effects. (2012) (92)
BEX2 is overexpressed in a subset of primary breast cancers and mediates nerve growth factor/nuclear factor-kappaB inhibition of apoptosis in breast cancer cell lines. (2007) (91)
The Specificity of the FOXL2 c.402C>G Somatic Mutation: A Survey of Solid Tumors (2009) (91)
A variational Bayesian mixture modelling framework for cluster analysis of gene-expression data (2005) (86)
Tandem duplication of chromosomal segments is common in ovarian and breast cancer genomes (2012) (86)
Intra-tumour genetic heterogeneity and poor chemoradiotherapy response in cervical cancer (2010) (77)
Boosting Wnt activity during colorectal cancer progression through selective hypermethylation of Wnt signaling antagonists (2014) (77)
Microarray segmentation methods significantly influence data precision. (2004) (75)
Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer (2017) (70)
Unraveling tumor–immune heterogeneity in advanced ovarian cancer uncovers immunogenic effect of chemotherapy (2020) (70)
Effects of Collection and Processing Procedures on Plasma Circulating Cell-Free DNA from Cancer Patients (2018) (69)
Sequencing Structural Variants in Cancer for Precision Therapeutics. (2016) (69)
Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma (2021) (68)
Shared heritability and functional enrichment across six solid cancers (2018) (67)
Evidence for a time-dependent association between FOLR1 expression and survival from ovarian carcinoma: implications for clinical testing. An Ovarian Tumour Tissue Analysis consortium study (2014) (65)
Promises and challenges of adoptive T-cell therapies for solid tumours (2021) (62)
Prognostic gene expression signature for high-grade serous ovarian cancer (2020) (61)
New paradigms for BRCA1/BRCA2 testing in women with ovarian cancer: results of the Genetic Testing in Epithelial Ovarian Cancer (GTEOC) study (2016) (59)
The role of tandem duplicator phenotype in tumour evolution in high‐grade serous ovarian cancer (2012) (59)
ICON8: A GCIG phase III randomised trial evaluating weekly dosedense chemotherapy integration in first- line epithelial ovarian/fallopian tube/primary peritoneal carcinoma (EOC) treatment: Results of primary progression- free survival (PFS) analysis (2017) (59)
Computational pathology of pre-treatment biopsies identifies lymphocyte density as a predictor of response to neoadjuvant chemotherapy in breast cancer (2016) (56)
Unraveling tumor–immune heterogeneity in advanced ovarian cancer uncovers immunogenic effect of chemotherapy (2018) (55)
MMASS: an optimized array-based method for assessing CpG island methylation (2006) (53)
A silencer element identified in Drosophila is required for imprinting of H19 reporter transgenes in mice. (1999) (52)
Expression microarray reproducibility is improved by optimising purification steps in RNA amplification and labelling (2004) (51)
Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an Ovarian Tumor Tissue Analysis consortium study (2018) (50)
Association between tumour infiltrating lymphocytes, histotype and clinical outcome in epithelial ovarian cancer (2017) (50)
Image-guided biopsy in patients with suspected ovarian carcinoma: a safe and effective technique? (2008) (47)
A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. (2018) (45)
ß3 integrin modulates transforming growth factor beta induced (TGFBI) function and paclitaxel response in ovarian cancer cells (2012) (44)
Apparent diffusion coefficient and vascular signal fraction measurements with magnetic resonance imaging: feasibility in metastatic ovarian cancer at 3 Tesla (2010) (44)
Dynamic contrast‐enhanced MRI in ovarian cancer: Initial experience at 3 tesla in primary and metastatic disease (2010) (43)
Repeatability of Quantitative FDG-PET/CT and Contrast-Enhanced CT in Recurrent Ovarian Carcinoma: Test–Retest Measurements for Tumor FDG Uptake, Diameter, and Volume (2014) (43)
A combination of the immunohistochemical markers CK7 and SATB2 is highly sensitive and specific for distinguishing primary ovarian mucinous tumors from colorectal and appendiceal metastases (2019) (41)
Models of endometriosis and their utility in studying progression to ovarian clear cell carcinoma (2015) (38)
A tumor DNA complex aberration index is an independent predictor of survival in breast and ovarian cancer (2014) (38)
Novel conserved elements upstream of the H19 gene are transcribed and act as mesodermal enhancers. (2002) (38)
Molecular profiling of breast cancer: portraits but not physiognomy (2000) (37)
Development of Cell‐Permeable, Non‐Helical Constrained Peptides to Target a Key Protein–Protein Interaction in Ovarian Cancer (2016) (37)
A-ring dihalogenation increases the cellular activity of combretastatin-templated tetrazoles. (2012) (37)
Metabolic characterization of primary and metastatic ovarian cancer by 1H‐MRS in vivo at 3T (2009) (37)
Two novel determinants of etoposide resistance in small cell lung cancer. (2011) (36)
A pan-cancer compendium of chromosomal instability (2022) (35)
Astronomical algorithms for automated analysis of tissue protein expression in breast cancer (2013) (35)
Genomic landscape of platinum resistant and sensitive testicular cancers (2020) (35)
One-stop diagnostic breast clinics: how often are breast cancers missed? (2009) (35)
Identification and Development of 2,3-Dihydropyrrolo[1,2-a]quinazolin-5(1H)-one Inhibitors Targeting Bromodomains within the Switch/Sucrose Nonfermenting Complex (2016) (34)
Refinement of prespecified cutoff for genomic loss of heterozygosity (LOH) in ARIEL2 part 1: A phase II study of rucaparib in patients (pts) with high grade ovarian carcinoma (HGOC). (2016) (34)
Exploratory Analysis of TP 53 Mutations in Circulating Tumour DNA as Biomarkers of Treatment Response for Patients with Relapsed High-Grade Serous Ovarian Carcinoma : A Retrospective Study (2016) (34)
Structural analysis of the genome of breast cancer cell line ZR-75-30 identifies twelve expressed fusion genes (2012) (34)
Microarrays and breast cancer clinical studies: forgetting what we have not yet learnt (2005) (33)
Bcl-2 and β1-integrin predict survival in a tissue microarray of small cell lung cancer (2010) (33)
Evaluation of nonenhancing tumor fraction assessed by dynamic contrast-enhanced MRI subtraction as a predictor of decrease in tumor volume in response to chemoradiotherapy in advanced cervical cancer. (2010) (32)
A metadata approach for clinical data management in translational genomics studies in breast cancer (2009) (31)
Lymphocyte density determined by computational pathology validated as a predictor of response to neoadjuvant chemotherapy in breast cancer: secondary analysis of the ARTemis trial (2017) (31)
Genomic analysis of the 8p11‐12 amplicon in familial breast cancer (2007) (31)
Integrative Kinome Profiling Identifies mTORC1/2 Inhibition as Treatment Strategy in Ovarian Clear Cell Carcinoma (2018) (30)
Paclitaxel resistance increases oncolytic adenovirus efficacy via upregulated CAR expression and dysfunctional cell cycle control (2015) (29)
European Experts Consensus: BRCA/Homologous Recombination Deficiency Testing in First-Line Ovarian Cancer. (2021) (29)
TGFBI Production by Macrophages Contributes to an Immunosuppressive Microenvironment in Ovarian Cancer (2021) (29)
Critical questions in ovarian cancer research and treatment: Report of an American Association for Cancer Research Special Conference (2019) (29)
Genetic Data from Nearly 63,000 Women of European Descent Predicts DNA Methylation Biomarkers and Epithelial Ovarian Cancer Risk. (2018) (29)
Tissue-specific and interpretable sub-segmentation of whole tumour burden on CT images by unsupervised fuzzy clustering (2020) (29)
Molecular pathogenesis of ovarian clear cell carcinoma. (2015) (29)
SPARC Regulates Transforming Growth Factor Beta Induced (TGFBI) Extracellular Matrix Deposition and Paclitaxel Response in Ovarian Cancer Cells (2016) (28)
Absence of p300 induces cellular phenotypic changes characteristic of epithelial to mesenchyme transition (2006) (28)
Selecting short DNA fragments in plasma improves detection of circulating tumour DNA (2017) (28)
A Bayesian adaptive design for biomarker trials with linked treatments (2015) (28)
Germline whole exome sequencing and large-scale replication identifies FANCM as a likely high grade serous ovarian cancer susceptibility gene. (2017) (28)
Ovarian clear cell carcinoma—bad endometriosis or bad endometrium? (2011) (27)
Methanol-based fixation is superior to buffered formalin for next-generation sequencing of DNA from clinical cancer samples (2015) (27)
Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE) (2020) (27)
2700 Final results of ARIEL2 (Part 1): A phase 2 trial to prospectively identify ovarian cancer (OC) responders to rucaparib using tumor genetic analysis (2015) (26)
Clinical and pathological associations of PTEN expression in ovarian cancer: a multicentre study from the Ovarian Tumour Tissue Analysis Consortium (2020) (25)
Tissue Banking of Diagnostic Lung Cancer Biopsies for Extraction of High Quality RNA (2010) (25)
Antivascular and anticancer activity of dihalogenated A-ring analogues of combretastatin A-4 (2010) (23)
Metabolic consequences of p300 gene deletion in human colon cancer cells. (2006) (23)
Integrative radiogenomics for virtual biopsy and treatment monitoring in ovarian cancer (2020) (23)
Population-based targeted sequencing of 54 candidate genes identifies PALB2 as a susceptibility gene for high-grade serous ovarian cancer (2019) (22)
Functional genomic analysis of drug sensitivity pathways to guide adjuvant strategies in breast cancer (2008) (22)
MyD88 and TLR4 Expression in Epithelial Ovarian Cancer (2018) (21)
Total syntheses of subereamollines A and B. (2011) (21)
High-resolution array-CGH and expression profiling identifies a novel genomic subtype of ER negative breast cancer (2007) (21)
Diffusion-weighted MRI in Advanced Epithelial Ovarian Cancer: Apparent Diffusion Coefficient as a Response Marker. (2019) (21)
Integration of proteomics with CT-based qualitative and radiomic features in high-grade serous ovarian cancer patients: an exploratory analysis (2020) (19)
Absence of p300 induces cellular phenotypic changes characteristic of epithelial to mesenchyme transition (2006) (19)
Detection of ctDNA from Dried Blood Spots after DNA Size Selection. (2020) (19)
Metadata-driven software for clinical trials (2009) (19)
Increased endothelial cell selectivity of triazole-bridged dihalogenated A-ring analogues of combretastatin A-1. (2012) (18)
Predictive cancer genomics—what do we need? (2003) (18)
Total syntheses of the bromotyrosine-derived natural products ianthelline, 5-bromoverongamine and JBIR-44 (2010) (17)
Sequential genetic change at the TP53 and chemokine receptor CXCR4 locus during transformation of human ovarian surface epithelium (2011) (17)
Combining measures of immune infiltration shows additive effect on survival prediction in high-grade serous ovarian carcinoma (2020) (16)
Germline whole exome sequencing and large-scale replication identifies FANCM as a likely high grade serous ovarian cancer susceptibility gene (2017) (16)
Integrated Multi-Tumor Radio-Genomic Marker of Outcomes in Patients with High Serous Ovarian Carcinoma (2020) (15)
Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analyses (2020) (15)
PISARRO: A EUTROC phase Ib study of APR-246 in combination with carboplatin (C) and pegylated liposomal doxorubicin (PLD) in platinum sensitive relapsed high grade serous ovarian cancer (HGSOC). (2016) (15)
Abstract A27: The ovarian tumor tissue analysis (OTTA) consortium (2013) (14)
A randomized double-blind placebo-controlled phase II trial comparing gemcitabine monotherapy to gemcitabine in combination with adavosertib in women with recurrent, platinum resistant epithelial ovarian cancer: A trial of the Princess Margaret, California, Chicago and Mayo Phase II Consortia. (2019) (14)
Personalising Treatment for High-Grade Serous Ovarian Carcinoma. (2018) (13)
Ultrasound-guided targeted biopsies of CT-based radiomic tumour habitats: technical development and initial experience in metastatic ovarian cancer (2020) (12)
Universal BRCA1/BRCA2 Testing for Ovarian Cancer Patients is Welcomed, but with Care: How Women and Staff Contextualize Experiences of Expanded Access (2017) (12)
Epirubicin, Cisplatin, and Capecitabine for Primary Platinum-Resistant or Platinum-Refractory Epithelial Ovarian Cancer (2015) (12)
Sodium MRI with 3D-cones as a measure of tumour cellularity in high grade serous ovarian cancer (2019) (12)
Slingshot: a PiggyBac based transposon system for tamoxifen-inducible ‘self-inactivating’ insertional mutagenesis (2010) (12)
ARIEL 2/3: An integrated clinical trial program to assess activity of rucaparib in ovarian cancer and to identify tumor molecular characteristics predictive of response. (2014) (12)
Polygenic risk modeling for prediction of epithelial ovarian cancer risk (2022) (11)
215 Updated clinical and preliminary correlative results of ARIEL2, a Phase 2 study to identify ovarian cancer patients likely to respond to rucaparib (2014) (11)
Feasibility of monitoring response to the PARP inhibitor rucaparib with targeted deep sequencing of circulating tumor DNA (ctDNA) in women with high-grade serous carcinoma on the ARIEL2 trial. (2016) (11)
Refined characterization of circulating tumor DNA through biological feature integration (2021) (11)
Diffusion kurtosis MRI as a predictive biomarker of response to neoadjuvant chemotherapy in high grade serous ovarian cancer (2019) (10)
Can integrative biomarker approaches improve prediction of platinum and PARP inhibitor response in ovarian cancer? (2021) (10)
Feasibility of Quantitative Magnetic Resonance Fingerprinting in Ovarian Tumors for T1 and T2 Mapping in a PET/MR Setting (2019) (10)
Conditions Associated with Circulating Tumor-Associated Folate Receptor 1 Protein in Healthy Men and Women (2014) (10)
The Genomic Landscape of Early-Stage Ovarian High-Grade Serous Carcinoma (2021) (9)
The Xenopus Tgfbi is required for embryogenesis through regulation of canonical Wnt signalling. (2013) (9)
883PDPRELIMINARY RESULTS OF ARIEL2, A PHASE 2 OPEN-LABEL STUDY TO IDENTIFY OVARIAN CANCER PATIENTS LIKELY TO RESPOND TO RUCAPARIB. (2014) (8)
Safety and utility of image-guided research biopsies in relapsed high-grade serous ovarian carcinoma—experience of the BriTROC consortium (2017) (8)
Imprinting and gene silencing in mice and Drosophila. (1998) (7)
Optimal amounts of fluorescent dye improve expression microarray results in tumor specimens (2005) (7)
Immunohistochemistry and Next Generation Sequencing are Complementary Tests in Identifying PTEN Abnormality in Endometrial Carcinoma Biopsies (2020) (7)
Detection of ctDNA from dried blood spots after DNA size selection (2019) (6)
Sizing up mi RNAs as cancer genes (2005) (6)
Clinically Interpretable Radiomics-Based Prediction of Histopathologic Response to Neoadjuvant Chemotherapy in High-Grade Serous Ovarian Carcinoma (2022) (6)
You won't believe this old test … that does cheap single‐cell mutation detection (2018) (6)
EUTROC PiSARRO: A phase Ib study combining APR-246 with standard chemotherapy in platinum sensitive relapsed high grade serous ovarian carcinoma (HGSOC). (2015) (6)
Stem cells: Anatomy of an ovarian cancer (2013) (6)
PIK3R1W624R Is an Actionable Mutation in High Grade Serous Ovarian Carcinoma (2020) (6)
Biomarkers for site-specific response to neoadjuvant chemotherapy in epithelial ovarian cancer: relating MRI changes to tumour cell load and necrosis (2021) (6)
A randomized, placebo-controlled phase II trial comparing gemcitabine monotherapy to gemcitabine in combination with AZD 1775 (MK 1775) in women with recurrent, platinum-resistant epithelial ovarian, primary peritoneal, or Fallopian tube cancers: Trial of Princess Margaret, Mayo, Chicago, and Califo (2015) (6)
DNA Methylation Profiles of Ovarian Clear Cell Carcinoma (2021) (5)
Population exposure-efficacy and exposure-safety analyses for rucaparib in patients with recurrent ovarian carcinoma from Study 10 and ARIEL2. (2021) (5)
ICON8: An international randomized trial comparing two dose-dense regimens, 3-weekly carboplatin plus weekly paclitaxel (CwT), and weekly carboplatin-paclitaxel (wCwT), to standard 3-weekly treatment in women with newly diagnosed ovarian, fallopian tube, and primary peritoneal cancer. (2014) (5)
The genomic and immune landscape of long-term survivors of high-grade serous ovarian cancer (2022) (5)
Validated biomarker assays confirm that ARID1A loss is confounded with MMR deficiency, CD8+ TIL infiltration, and provides no independent prognostic value in endometriosis‐associated ovarian carcinomas (2021) (5)
Evaluation of vitamin D biosynthesis and pathway target genes reveals UGT2A1/2 and EGFR polymorphisms associated with epithelial ovarian cancer in African American Women (2019) (5)
Absolute copy number fitting from shallow whole genome sequencing data (2021) (5)
Molecular Subclasses of Clear Cell Ovarian Carcinoma and Their Impact on Disease Behavior and Outcomes (2022) (5)
Publisher Correction: Shared heritability and functional enrichment across six solid cancers (2019) (4)
PathGrid: a service-orientated architecture for microscopy image analysis (2010) (4)
Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes (2022) (4)
The Predictive Role of Functional Imaging in Cervix Cancer (2007) (4)
Computed Tomography Measures of Inter-site tumor Heterogeneity for Classifying Outcomes in High-Grade Serous Ovarian Carcinoma: a Retrospective Study (2019) (4)
805O ICON8: Overall survival results in a GCIG phase III randomised controlled trial of weekly dose-dense chemotherapy in first line epithelial ovarian, fallopian tube or primary peritoneal carcinoma treatment (2020) (4)
Profiling the immune landscape in mucinous ovarian carcinoma. (2022) (3)
Phase II open-label randomized multi-centre study of neoadjuvant olaparib in patients (pts) with platinum sensitive (PS) relapsed high grade serous ovarian cancer (OC): The NEO trial. (2017) (3)
Structural and calorimetric studies demonstrate that the hepatocyte nuclear factor 1β (HNF1β) transcription factor is imported into the nucleus via a monopartite NLS sequence (2016) (3)
Spatial and temporal heterogeneity in high-grade serous ovarian cancer: a phylogenetic reconstruction (2015) (3)
Longitudinal monitoring of disease burden and response using ctDNA from dried blood spots in xenograft models (2022) (3)
Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal cancer treatment (ICON8): overall survival results from an open-label, randomised, controlled, phase 3 trial (2022) (3)
Integrated efficacy and safety analysis of the poly(ADP-ribose) polymerase (PARP) inhibitor rucaparib in patients (pts) with high-grade ovarian carcinoma (HGOC) (2017) (3)
Cambridge Translational Cancer Research Ovarian Study 01 (CTCR-OV01): Expression profiling of advanced epithelial ovarian cancer (EOC) to predict chemotherapy response. A randomised phase II trial design with prospective translational endpoints. (2006) (3)
Somatic cancer genetics in the UK: real-world data from phase I of the Cancer Research UK Stratified Medicine Programme (2018) (3)
DNA Methylation Arrays : Methods and Analysis (2008) (3)
Assessment of clinical applications of circulating tumor DNA using an enhanced TAm-Seq platform. (2015) (3)
Intensive cisplatin/oral etoposide for epithelial ovarian cancer: the Cambridge Gynae-Oncology Centre experience too toxic for relapse? (2016) (3)
Clonal somatic copy number altered driver events inform drug sensitivity in high-grade serous ovarian cancer (2022) (3)
Copy number signatures and mutational processes in ovarian carcinoma (2018) (3)
A national platform for molecular diagnostics: Results of the Cancer Research UK Stratified Medicine Programme (2014) (3)
Response to neoadjuvant chemotherapy in ICON8: A GCIG phase III randomised trial evaluating weekly dose-dense chemotherapy integration in first-line epithelial ovarian/ fallopian tube/ primary peritoneal carcinoma (EOC) treatment. (2018) (3)
PISARRO: A EUTROC phase 1b study of APR-246 with carboplatin (C) and pegylated liposomal doxorubicin (PLD) in relapsed platinum-sensitive high grade serous ovarian cancer (HGSOC) (2016) (2)
Integrated radiogenomics models predict response to neoadjuvant chemotherapy in high grade serous ovarian cancer (2021) (2)
Targeted Deep Sequencing of Plasma DNA Noninvasive Identification and Monitoring of Cancer Mutations by (2012) (2)
Circulating tumour DNA for clinicians: current and future clinical applications. (2021) (2)
B Inhibition of Apoptosis in Breast Cancer Cell Lines κ Cancers and Mediates Nerve Growth Factor / Nuclear Factor-Is Overexpressed in a Subset of Primary Breast (2007) (2)
Prognostic and Immunological Significance of ARID1A Status in Endometriosis-Associated Ovarian Carcinoma (2021) (2)
Robust identification of novel prognostic gene-signatures in breast cancer (2006) (2)
Copy number alterations in stage I epithelial ovarian cancer highlight three genomic patterns associated with prognosis. (2022) (2)
Bex2 identifies a novel subtype of breast cancer associated with estrogen-response and NGF/NF-KB pathway (2006) (2)
Complex Stiffness Gradient Substrates for Studying Mechanotactic Cell Migration (Adv. Mater. 45/2012) (2012) (2)
A metadata-aware application for remote scoring and exchange of tissue microarray images (2013) (2)
Proteomic Analysis of Transitional Cell Carcinoma-Like Variant of Tubo-Ovarian High-Grade Serous Carcinoma. (2020) (2)
Circulating tumour DNA carrying patient-specific mutations in TP53 as an early response biomarker in relapsed high grade serous ovarian cancer. (2016) (2)
Allele-informed copy number evaluation of plasma DNA samples from metastatic prostate cancer patients: the PCF_SELECT consortium assay (2022) (2)
Population exposure-safety and exposure-efficacy analyses for rucaparib in patients (pts) with recurrent ovarian carcinoma (rOC) from Study 10 and ARIEL2 (2020) (2)
Abstract 1535: Immunohistochemistry predicts presence and type of TP53 mutation in high-grade serous carcinoma (2014) (2)
Somatic chromosomal number alterations affecting driver genes inform in-vitro and clinical drug response in high-grade serous ovarian cancer (2020) (1)
A metadata-aware application for remote scoring and exchange of tissue microarray images (2013) (1)
Combined image and genomic analysis of high-grade serous ovarian cancer reveals PTEN loss as a common driver event and prognostic classifier (2014) (1)
In reply [3] (2006) (1)
Abstract CT204: Preliminary results from PiSARRO, a phase Ib/II study of APR-246, a mutant p53 reactivating small molecule, in combination with standard chemotherapy in platinum-sensitive ovarian cancer (2015) (1)
A phase I , fi rst in human study of FP-1039 ( GSK 3052230 ) , a novel FGF ligand trap , in patients with advanced solid tumors (2016) (1)
Feasibility of monitoring response to the PARP inhibitor rucaparib with targeted deep sequencing of circulating tumor DNA (ctDNA) in women with high grade ovarian carcinoma on the ARIEL2 trial (2016) (1)
Combining measures of immune infiltration shows additive effect on survival prediction in high-grade serous ovarian carcinoma (2020) (1)
Prolonged response of relapsed high grade serous ovarian carcinoma to the oral angiokinase inhibitor nintedanib in a patient with a germline BRCA1 mutation. (2012) (1)
FrenchFISH: Poisson Models for Quantifying DNA Copy Number From Fluorescence In Situ Hybridization of Tissue Sections (2021) (1)
Abstract AP28: BRCA1 and RAD51C Promoter Hypermethylation Confer Sensitivity to PARP Inhibitors in Patients with Platinum Sensitive Ovarian Carcinoma (2017) (1)
Abstract 278: No cell left behind: Residual ovarian spheroids drive recurrence and are sensitive to the pro-oxidant elesclomol (2016) (1)
Abstract A14: TP53 missense mutations associate with different metabolic pathways (2018) (1)
Metabolic Consequences of p 300 Gene Deletion in Human Colon Cancer Cells (2006) (1)
Identification of germline and somatic alterations in homologous recombination pathway genes in high grade ovarian carcinomas and response to the PARP inhibitor rucaparib in ARIEL2 (2016) (1)
Structural analysis of the genome of breast cancer cell line ZR-75-30 identifies twelve expressed fusion genes (2012) (1)
Correction: Safety and utility of image-guided research biopsies in relapsed high-grade serous ovarian carcinoma—experience of the BriTROC consortium (2019) (1)
Prolonged response of relapsed high grade serous ovarian carcinoma to the oral angiokinase inhibitor nintedanib in a patient with a germline BRCA1 mutation. (2013) (1)
High-grade serous ovarian carcinoma organoids as models of chromosomal instability (2022) (1)
Multiparameter single-cell proteomic technologies give new insights into the biology of ovarian tumors (2023) (1)
The genomic landscape of recurrent ovarian high grade serous carcinoma: the BriTROC-1 study (2022) (1)
Boosting Wnt activity during colorectal cancer progression through selective hypermethylation of Wnt signaling antagonists (2014) (1)
Kinome capture sequencing of high-grade serous ovarian carcinoma reveals novel mutations in the JAK3 gene (2020) (1)
151PDARID1A ROLE IN CELL CYCLE REGULATION AND PROLIFERATION IN MOUSE AND HUMAN GYNAECOLOGICAL TISSUES REVEALS POTENTIAL THERAPEUTIC TARGETS. (2014) (1)
Correction: Polygenic risk modeling for prediction of epithelial ovarian cancer risk (2022) (1)
Increased FOXJ1 protein expression is associated with improved overall survival in high-grade serous ovarian carcinoma: an Ovarian Tumor Tissue Analysis Consortium Study (2022) (1)
S94 Two novel determinants of etoposide resistance in small cell lung cancer (2010) (1)
Polygenic Risk Modelling for Prediction of Epithelial Ovarian Cancer Risk (2020) (1)
Clinical and pathological associations of PTEN expression in ovarian cancer: a multicentre study from the Ovarian Tumour Tissue Analysis Consortium (2020) (1)
Biomarkers for site-specific response to neoadjuvant chemotherapy in epithelial ovarian cancer: relating MRI changes to tumour cell load and necrosis (2021) (1)
Abstract 1677: Assays of conventional chemotherapeutics and targeted drugs for ovarian cancer using patient derived models (2020) (0)
7P Integration of whole genome sequencing (WGS) into NHS pathways for high-grade ovarian cancer (HGOC): A single-centre prospective experience (2023) (0)
Magnetization transfer imaging of ovarian cancer: initial experiences of correlation with tissue cellularity and changes following neoadjuvant chemotherapy (2022) (0)
Advanced cervix cancer : Can simple DCE-MRI derived parameters predict treatment response ? (2005) (0)
Genetic heterogeneity in solid tumours and its effect on drug response (2010) (0)
PO-489 TP53 mutations and focal genomic amplifications for ctDNA detection in high-grade serous ovarian carcinoma (2018) (0)
The nature and development of cancer: Cancer mutations and their implications (2020) (0)
Lesion-specific 3D-printed moulds for image-guided tissue multi-sampling of ovarian tumours: A prospective pilot study (2023) (0)
p53 and ovarian carcinoma survival: an Ovarian Tumor Tissue Analysis consortium study (2023) (0)
PO-483 Improved sensitivity for non-invasive diagnosis of high-grade serous ovarian cancer (2018) (0)
Calibrating Ensembles for Scalable Uncertainty Quantification in Deep Learning-based Medical Segmentation (2022) (0)
NGS-based tumor genomic profiling to identify ovarian cancer patients who benefit from the PARP inhibitor rucaparib. (2016) (0)
Highlights from the 2014 American Association for Cancer Research Annual Meeting (2014) (0)
Metamodel-Based Generation of WSRF-Compliant SOA for Collaborative Cancer Research (2008) (0)
Computational pathology of pre-treatment biopsies identifies lymphocyte density as a predictor of response to neoadjuvant chemotherapy in breast cancer (2016) (0)
Additional file 7: of Computational pathology of pre-treatment biopsies identifies lymphocyte density as a predictor of response to neoadjuvant chemotherapy in breast cancer (2016) (0)
Additional file 9: of Computational pathology of pre-treatment biopsies identifies lymphocyte density as a predictor of response to neoadjuvant chemotherapy in breast cancer (2016) (0)
P38: DNA copy number changes predicting resistance to therapy in ovarian cancer patients (2005) (0)
Additional file 2: of Computational pathology of pre-treatment biopsies identifies lymphocyte density as a predictor of response to neoadjuvant chemotherapy in breast cancer (2016) (0)
Abstract AP09: COPY-NUMBER SIGNATURES AND MUTATIONAL PROCESSES IN HIGH GRADE SEROUS OVARIAN CARCINOMA (2019) (0)
255 Correlating dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) with changes in tumour volume, as a predictor of radiation response in cervix cancer (2006) (0)
Research data supporting '2,3-dihydropyrrolo[1,2-a]quinazolin-5(1H)-one inhibitors targeting bromodomains within the Switch/Sucrose Non-Fermenting complex'. (2016) (0)
Gynaecological Cancers: Predictive biology of ovarian cancer (2011) (0)
Polygenic risk modeling for prediction of epithelial ovarian cancer risk (2022) (0)
Polygenic risk modeling for prediction of epithelial ovarian cancer risk (2022) (0)
New Insights into Tubulin Binders (2011) (0)
DNA Methylation Pro ﬁ les of Ovarian Clear Cell Carcinoma (2021) (0)
A NOVEL TRANSLATIONAL DESIGN TO INVESTIGATE THE ROLE OF TP53 IN PREDICTING CARBOPLATIN RESPONSE IN ADVANCED OVARIAN CARCINOMA (2004) (0)
Diffusion kurtosis MRI as a predictive biomarker of response to neoadjuvant chemotherapy in high grade serous ovarian cancer (2019) (0)
Rare germline genetic variation in PAX8 transcription factor binding sites and susceptibility to epithelial ovarian cancer (2023) (0)
Shared heritability and functional enrichment across six solid cancers (2019) (0)
Correction: Safety and utility of image-guided research biopsies in relapsed high-grade serous ovarian carcinoma—experience of the BriTROC consortium (2019) (0)
Abstract 4976: Combining measures of immune infiltration uncovers predictors of survival in high-grade serous ovarian cancer (2020) (0)
Ovarian cancer pathology characteristics as predictors of variant pathogenicity in BRCA1 and BRCA2. (2023) (0)
CALIBRATE: Intensive profiling of circulating tumour DNA (ctDNA) from patients participating in experimental therapeutics trials including mutational profiles and copy number changes. (2016) (0)
Correction: Polygenic risk modeling for prediction of epithelial ovarian cancer risk (2022) (0)
Correction: Polygenic risk modeling for prediction of epithelial ovarian cancer risk (2022) (0)
Copy Number Variants Are Ovarian Cancer Risk Alleles at Known and Novel Risk Loci (2022) (0)
P112 Activation of PIK3CA in a model of endometriosis may shed light on the pathogenesis of ovarian clear cell adenocarcinoma (2019) (0)
Edinburgh Research Explorer Somatic Cancer Genetics in the UK: Real-World Data from Phase One of the Cancer Research UK Stratified Medicine Programme (2018) (0)
Abstract IA19: Intratumoral heterogeneity and drug response in high-grade serous carcinoma (2013) (0)
β3 integrin modulates transforming growth factor beta induced (TGFBI) function and paclitaxel response in ovarian cancer cells (2012) (0)
Explorer Genomic analysis of genetic heterogeneity and evolution in high-grade serous ovarian carcinoma (2017) (0)
Genetically predicted DNA methylation biomarkers and epithelial ovarian cancer risk: data from nearly 63,000 women of European descent (2019) (0)
Abstract A25: PPP2R1A mutations affect PP2A complex formation, and novel protein interactions in gynecological carcinoma cell lines (2013) (0)
Critical Questions in Ovarian Cancer Research and Treatment: Report of an AACR Special Conference (2019) (0)
Lifestyle and personal factors associated with having macroscopic residual disease after ovarian cancer primary cytoreductive surgery. (2022) (0)
Abstract 2412: Assessment of clinical applications of circulating tumor DNA using an enhanced TAm-Seq platform (2015) (0)
Importin-alpha in complex with HNF1-beta peptide (2016) (0)
LGR5 targeting molecules as therapeutic agents for multiple cancer types (2022) (0)
Abstract AP27: FEASIBILITY OF MONITORING RESPONSE TO THE PARP INHIBITOR RUCAPARIB WITH TARGETED DEEP SEQUENCING OF CIRCULATING TUMOR DNA (CTDNA) IN WOMEN WITH HIGH GRADE OVARIAN CARCINOMA ON THE ARIEL2 TRIAL (2017) (0)
Association between tumour infiltrating lymphocytes, histotype and clinical outcome in epithelial ovarian cancer (2017) (0)
CCNE1 and survival of patients with tubo‐ovarian high‐grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium study (2022) (0)
Additional file 1: of Computational pathology of pre-treatment biopsies identifies lymphocyte density as a predictor of response to neoadjuvant chemotherapy in breast cancer (2016) (0)
D R A F T Integrated radiogenomics models predict response to neoadjuvant chemotherapy in high grade serous ovarian cancer (2021) (0)
COPY-NUMBER SIGNATURES AND MUTATIONAL PROCESSES IN HIGH GRADE SEROUS OVARIAN CARCINOMA (2019) (0)
A Prospective Randomized Translational Study for the Molecular Individualization of Carboplatin and Paclitaxel Treatment of Advanced Epithelial Ovarian Cancer (2003) (0)
Additional file 3: of Computational pathology of pre-treatment biopsies identifies lymphocyte density as a predictor of response to neoadjuvant chemotherapy in breast cancer (2016) (0)
Additional file 6: of Computational pathology of pre-treatment biopsies identifies lymphocyte density as a predictor of response to neoadjuvant chemotherapy in breast cancer (2016) (0)
Additional file 5: of Computational pathology of pre-treatment biopsies identifies lymphocyte density as a predictor of response to neoadjuvant chemotherapy in breast cancer (2016) (0)
Additional file 12: of Computational pathology of pre-treatment biopsies identifies lymphocyte density as a predictor of response to neoadjuvant chemotherapy in breast cancer (2016) (0)
Abstract 5879: Spatially-segmented single-cell transcriptomics by diffusional accessibility to a small-molecule dye (2020) (0)
Abstract CT339: Prospective molecular identification of ovarian cancer patients benefiting from PARP inhibitor (PARPi, rucaparib) maintenance therapy - reaching beyond germline BRCA mutations (2014) (0)
Abstract GMM-048: CTDNA RESPONSE TO THE PARP INHIBITOR RUCAPARIB PREDICTS PROGRESSION-FREE SURVIVAL AND BEST OVERALL RESPONSE ON THE ARIEL2 TRIAL (2019) (0)
Clonal expansion index stratifies patients into prognostic subgroups. (2015) (0)
Additional file 4: of Computational pathology of pre-treatment biopsies identifies lymphocyte density as a predictor of response to neoadjuvant chemotherapy in breast cancer (2016) (0)
28MO Real-world whole sequencing data of ovarian cancer patients (2022) (0)
Deep learning-based Segmentation of Multi-site Disease in Ovarian Cancer (2023) (0)
Additional file 8: of Computational pathology of pre-treatment biopsies identifies lymphocyte density as a predictor of response to neoadjuvant chemotherapy in breast cancer (2016) (0)
2022-RA-1058-ESGO Developing infrastructure for molecular profiling for all in ovarian cancer (DEMO) (2022) (0)
Array comparative genome hybridization (aCGH) of high risk breast cancer reveals ERBB2 and MYC coamplification (2001) (0)
Author ’ s response to reviews Title : Association between tumour infiltrating lymphocytes , histotype and clinical outcome in epithelial ovarian cancer (2017) (0)
Author ’ s response to reviews Title : Association between tumour infiltrating lymphocytes , histotype and clinical outcome in epithelial ovarian cancer (2017) (0)
FrenchFISH: Poisson models for quantifying DNA copy-number from fluorescence in situ hybridisation of tissue sections (2018) (0)
Forshew 1..12 (2019) (0)
Molecular landscape and functional characterization of centrosome amplification in ovarian cancer (2023) (0)
575P Homologous recombination deficiency in newly diagnosed FIGO stage III/IV high-grade serous or endometrioid ovarian cancer: A multi-national observational study (2022) (0)
Combination of mTOR inhibition and paclitaxel as a personalised strategy in the context of MYC-amplified high-grade serous ovarian cancer (2019) (0)
EP361/#717 Developing infrastructure for molecular profiling in ovarian cancer (DEMO) (2022) (0)
Genomic Applications in Epithelial Ovarian Malignancies (2015) (0)
Predicting response to cytotoxic chemotherapy (2023) (0)
Additional file 11: of Computational pathology of pre-treatment biopsies identifies lymphocyte density as a predictor of response to neoadjuvant chemotherapy in breast cancer (2016) (0)
Genomic landscape of platinum resistant and sensitive testicular cancers (2020) (0)
Gene expression A variational Bayesian mixture modelling framework for cluster analysis of gene-expression data (2005) (0)
Chromosomal instability determines taxane sensitivity - supplementary materials (2009) (0)
Abstract 53: The copy number landscape of early stage ovarian high grade serous carcinoma (2022) (0)
Genomic Applications in Ovarian Cancer (2018) (0)
Abstract IA12: The Ovarian Tumour Tissue Analysis Consortium: Stratified Prognosis of Ovarian Tumors (OTTA-SPOT) signature for high-grade serous ovarian cancer (2020) (0)
Genomic analysis of early-stage lung cancer reveals a role for TP53 mutations in distant metastasis (2022) (0)
Rockall, Andrea G. et al. (2014) Repeatability of quantitative FDG-PET/CT and contrast enhanced CT in recurrent ovarian carcinoma: test retest (2008) (0)
33P The development of infrastructure for mainstream ovarian cancer genetic testing (DEMO) (2022) (0)
High Prediagnosis Inflammation-Related Risk Score Associated with Decreased Ovarian Cancer Survival (2021) (0)
Homologous recombination deficiency in newly diagnosed FIGO stage III/IV high-grade epithelial ovarian cancer: a multi-national observational study (2023) (0)
0241: A Randomised Phase II Trial in Advanced Epithelial Ovarian Cancer (Eoc), with Prospective Translational End-Points to Predict Chemotherapy Response (Ctcr-Ov01) (2006) (0)
Hierarchical clustering of 26 cell lines and 267 ovarian carcinomas based on the expression of the 1141 morphological subtypes-associated genes (A) and the association with progression-free survival (B). (2014) (0)
Abstract IA17: Physical and in silico methods for improving sensitivity of detection of ctDNA for personalized medicine in high-grade serous ovarian cancer (2018) (0)

This paper list is powered by the following services:

Other Resources About James D. Brenton

en.wikipedia.org

What Schools Are Affiliated With James D. Brenton?

James D. Brenton is affiliated with the following schools: